Company Description
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded ...
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Valuation
Price to Book Ratio
3.92
Total Debt to Enterprise Value
0.08
Efficiency
Income Per Employee
-978,732.00
Liquidity
Current Ratio
14.83
Quick Ratio
14.83
Cash Ratio
14.26
Profitability
Return on Assets
-57.92
Return on Equity
-65.51
Return on Total Capital
-61.80
Return on Invested Capital
-60.65
Capital Structure
Total Debt to Total Equity
24.39
Total Debt to Total Capital
19.61
Total Debt to Total Assets
18.53
Long-Term Debt to Equity
23.20
Long-Term Debt to Total Capital
18.65
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Dr. Richard A. Moscicki | 67 | 2018 | Independent Director |
| Mr. Frédéric Chéreau | 53 | 2016 | President, Chief Executive Officer & Director |
| Dr. Kyle Chiang | 40 | 2016 | Chief Operating Officer |
| Mr. Jonathan Quick | - | 2019 | Senior Finance Director |
| Ms. Cecilia Jones | 45 | 2021 | Chief Financial Officer |
Insider Actions
| 01/01/2021 |
Mark A. Kay Director |
2,199 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/01/2021 |
Leon E. Chen Director |
3,298 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/01/2021 |
Richard A. Moscicki Director |
3,916 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/01/2021 |
Michael S. Wyzga Director |
3,141 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/01/2021 |
Mark J. Enyedy Director |
2,921 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 12/10/2020 |
Daniel O’Connell Director |
2,513 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 09/25/2020 |
Arix Bioscience Plc |
174,219 | Disposition at $7.08 per share. | 1,233,470 |
| 09/24/2020 |
Arix Bioscience Plc |
38,514 | Disposition at $7.63 per share. | 293,861 |
| 08/13/2020 |
Arix Bioscience Plc |
159 | Disposition at $8.75 per share. | 1,391 |
| 08/12/2020 |
Arix Bioscience Plc |
1,335 | Disposition at $8.79 per share. | 11,734 |
| 07/29/2020 |
Arix Bioscience Plc |
2,709 | Disposition at $8.78 per share. | 23,785 |
| 07/22/2020 |
Arix Bioscience Plc |
22,651 | Disposition at $9 per share. | 203,859 |
| 07/20/2020 |
Arix Bioscience Plc |
36,983 | Disposition at $9.25 per share. | 342,092 |
| 07/17/2020 |
Arix Bioscience Plc |
31,101 | Disposition at $9.24 per share. | 287,373 |
MarketWatch News on LOGC
No News currently available for LOGC
Other News on LOGC
-
LogicBio Therapeutics names new CFO
- Seeking Alpha
-
- Seeking Alpha
-
10-Q: LOGICBIO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
LogicBio Therapeutics announces executive leadership changes
- Seeking Alpha
-
LogicBio Therapeutics (LOGC) Investor Presentation - Slideshow
- Seeking Alpha
-
BBBY, AMAG, GNFT and ZSAN among midday movers
- Seeking Alpha
-
LogicBio therapeutics -30% on pricing of equity offering
- Seeking Alpha
-
GNW, SELB among premarket losers
- Seeking Alpha
-
EXAS, OMI, GLNG and DGLY among midday movers
- Seeking Alpha
-
BB, CODX among premarket gainers
- Seeking Alpha
-
10-Q: LOGICBIO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
10-Q: LOGICBIO THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
- Loading more headlines...
